Mdxhealth Posts 92% Six-Year Survival in 409-Patient GPS-ProMPT Study
MDXH•Mdxhealth published Oxford GPS-ProMPT study demonstrating that 409 localized prostate cancer patients with favorable GPS mdx scores achieved 92% six-year failure-free survival on active surveillance and 100% in surgery and radiotherapy cohorts. This peer-reviewed milestone establishes basis for the GPS-ProtecT randomized trial to validate GPS mdx in clinical guidelines.
1. Publication Milestone
Mdxhealth published the peer-reviewed Oxford GPS-ProMPT study in European Urology Oncology as the first major milestone of its collaboration with the University of Oxford.
2. Study Results
The study tracked 409 men with localized or locally advanced prostate cancer for over six years, showing 92% failure-free survival in active surveillance and 100% in surgery and radiotherapy cohorts for patients with favorable GPS mdx scores.
3. Foundation for GPS-ProtecT Trial
These findings establish the scientific basis for the GPS-ProtecT randomized controlled trial, initiated on January 6, 2026, aiming to validate GPS mdx as the first genomic classifier supported by randomized clinical trial evidence.
4. Commercial and Clinical Impact
The peer-reviewed publication bolsters efforts to integrate GPS mdx into clinical guidelines, strengthen payer reimbursement cases, and drive physician adoption of the genomic assay for personalized prostate cancer management.
